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Abstract
Recent advances allow multiplexed genome engineering in E. coli, employing easily designed oligonucleotides to edit
multiple loci simultaneously. A similar technology in human cells would greatly expedite functional genomics, both by
enhancing our ability to test how individual variants such as single nucleotide polymorphisms (SNPs) are related to specific
phenotypes, and potentially allowing simultaneous mutation of multiple loci. However, oligo-mediated targeting of human
cells is currently limited by low targeting efficiencies and low survival of modified cells. Using a HeLa-based EGFP-rescue
reporter system we show that use of modified base analogs can increase targeting efficiency, in part by avoiding the
mismatch repair machinery. We investigate the effects of oligonucleotide toxicity and find a strong correlation between the
number of phosphorothioate bonds and toxicity. Stably EGFP-corrected cells were generated at a frequency of ,0.05% with
an optimized oligonucleotide design combining modified bases and reduced number of phosphorothioate bonds. We
provide evidence from comparative RNA-seq analysis suggesting cellular immunity induced by the oligonucleotides might
contribute to the low viability of oligo-corrected cells. Further optimization of this method should allow rapid and scalable
genome engineering in human cells.
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Introduction
New sequencing technologies are producing a wealth of data,
and soon it will be possible to sequence full human genomes for
about $1000 [1–2]. Unfortunately, our current ability to sequence
and identify genetic variants greatly outpaces our ability to
characterize their functional consequences. Genome-wide associ-
ation studies (GWAS) have revealed many single-nucleotide
polymorphisms (SNPs) linked to disease phenotypes, most of
which are ‘tag SNPs’ in the context of large genomic regions where
the actual causal variants remain unknown [3]. As of this writing,
NHGRI’s GWAS Catalog contains 6,030 SNPs with a p-value
,1.0610
25. Ultimately, potential causal variants linked to these
SNPs need to be experimentally tested. Traditionally, targeted
genetic modifications are achieved by selecting for rare homolo-
gous recombination(HR) events using a donor DNA that carries
the desired mutation as well as a selectable gene marker; after
selection, the marker may be removed using a targeted
recombinase such as Cre. However, the throughput of this
approach is limited by the extremely low frequency of HR(10
25–
10
27) in human cells and the serial clonal isolation steps [4]. In
addition, selection markers or residual recombinase sequences
could confound subtle phenotypes such as those caused by variants
in regulatory regions, which are of particular interest since
expression variability of ,5% of all human genes is linked to
SNPs located within 200 kb of the gene [5].
Custom targeted zinc-finger nucleases (ZFNs) [6], and more
recently transcription activator-like effector nucleases(TALENs)
[7] have shown great promise by increasing homologous
recombination rates to up to ,20%, which allows screening of
seamlessly-modified cells. ZFNs can be used with ,120 bp single-
stranded oligonucleotides, which greatly simplifies donor DNA
preparation [8]. However, production of custom nucleases for
each new locus is dependent on knowledge of protein-DNA
binding specificities, laborious design and optimization methods or
expensive commercial licensing [9–11]. In addition, the potential
for multiplexing custom targeted nucleases may be limited since
multiple double strand breaks could lead to gross genome
rearrangements or deletions [12–13]. Thus, a different genome
engineering technology will be necessary to keep up with the
demand for post-GWAS functional characterizations.
Oligonucleotide-mediated targeting is an alternative strategy for
genome engineering [14], in which mutation-encoding oligonu-
cleotides modify the genome without the need for custom-designed
DNA-binding proteins. The inherent simplicity and scalability of
this method makes it particularly well suited for generating a large
number of genetic variants. In E. coli l Red-mediated oligonucle-
otide recombineering, an oligo preferentially anneals to the lagging
strand of the genome during DNA replication and incorporates
into the daughter strand [15]. This has been optimized to achieve
targeting efficiencies as high as 20%, and when performed with
multiplexed degenerate oligos can generate .4610
6 combinato-
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in mammalian cells, with reported gene targeting frequencies of up
to 2% [17–20]. There is strong evidence showing oligo incorpo-
ration [18] and strand bias [21–22]. Similarly to E. coli, the
endogenous mismatch repair (MMR) machinery has been found
to inhibit oligo incorporation in mammalian cells [20,23–24], and
oligos modified with phosphorothioate (PTO) bonds to prevent
nuclease degradation have been found to increase targeting
efficiencies [20].
The main limitation of oligonucleotide-mediated targeting in
mammalian cells is the low survival of modified cells, with only a
few studies having demonstrated long-term survival and prolifer-
ation of corrected clones. To increase survival, the use of
unprotected oligos has been suggested [25], [18], however this
also makes corrections too low for multiplexed genome engineer-
ing. Here we describe our progress towards surpassing these
limitations. Using an EGFP-rescue based reporter system in HeLa
cells [19], we find that the use of commercially available
chemically modified base analogs to encode the mismatch in the
targeting oligo increase its frequency of incorporation, similar to
results in E. coli [26]. We also find that the number of PTO
modifications correlate with both the toxicity of oligo transfection
and the proliferation of oligo-modified cells, and having 3–5 PTO
bonds 3’ to the mismatch produced a .10-fold increase in stable
targeting compared to an unmodified oligos. Applying these oligo
design principles we were able to stably correct a mutant EGFP
with an efficiency of ,0.05% in HeLa cells. Finally, we compared
the transcription profiles of EGFP-corrected and -uncorrected cells
via RNA-seq and find upregulation of many genes associated with
cellular immunity. We propose a new model explaining the
toxicity in oligo-mediated recombination in human cells, where
cells that uptake more oligo are more likely to become corrected,
and likewise these cells are more likely to activate cellular immune
responses. Future exploration of this cellular response to trans-
fected oligos may lead to novel strategies for reducing their toxicity
and eventually enable multiplexed genome engineering in human
cells.
Results
Mismatch-specific EGFP Correction
To improve human genome engineering with oligonucleotides,
we worked with a well-characterized reporter system [19]
consisting of a HeLa cell line with two stably integrated copies
of a modified EGFP gene (mEGFP). This version of EGFP has a
non-functional start codon (TTG) which can be rescued by
targeting oligos (Figure 1a, Table 1) encoding for a functional
ATG, thus the oligo-mediated targeting efficiency can be
determined by flow cytometry as the percentage EGFP+ cells
(Fig. 1b). We confirmed previous findings [27] where targeting
mEGFP with a 25 bp long oligo complementary to the non-
transcribed strand and carrying a centrally located mismatch and
six PTO bonds at each end (F5-3, Fig. 1c) delivered with
Lipofectamine 2000 yielded a substantial proportion of EGFP+
cells after 48 hours (,0.5%), and this efficiency was further
increased to ,2% by slowing down DNA replication with
thymidine treatment. Other cationic lipid transfection reagents
resulted in lower efficiencies, possibly due to low nuclear
accumulation of the oligo (Figures S1,S2). Alternative delivery
methods such as electroporation and nucleofection failed to
produce any significant proportion of EGFP+ cells (not shown). An
oligo complementary to the transcribed strand, F5-2, did not
produce any EGFP+ cells significantly different from background.
Transfection of an oligo encoding an alternative ATG-restoring
mutation 9 bp away from the first site resulted in ,0.4% EGFP+
cells (F5-5, Fig. 1a,c), whereas an oligo carrying a non-coding
mismatch (F5-6, Fig. 1c) did not produce EGFP+ cells, demon-
strating that the expression of EGFP depends on the targeting
oligo sequence restoring the ORF. To further verify that EFGP+
cells had undergone the desired genomic modification, EGFP+
and – cells were sorted out by fluorescent-activated cell sorting
(FACS) and genotyped by allele-specific qPCR (AS-qPCR). The
EGFP+ population was estimated by AS-qPCR to carry 11–13%
converted DNA, which matches the 12.5% expected if these cells
have undergone a single oligo incorporation at one of the two
genomic mEGFP during DNA replication (1/8 strands at the end
of S phase) but not yet proceeded through cell division. In the
EGFP- population, the proportion of corrected alleles was
estimated to be ,1%, which may either represent corrected cells
that had not yet produced functional EGFP protein or PCR
artifacts caused by residual targeting oligonucleotides in the cells
[28].
Modified Bases Increase Efficiency in Part by Avoiding
Mismatch Repair in Mammalian Cells
Previous work has shown that the MMR machinery plays a
significant role recognizing and removing the mutation caused by
the oligo incorporation event. Currently, the only way around this
is by either completely knocking down one of the main MMR
proteins (e.g. MSH2) or by transient silencing with RNAi [29].
Our group recently showed an alternative strategy in E. coli, where
the oligo contains chemically modified bases that avoid mismatch
repair recognition. We tested oligos complementary to the non-
transcribed strands of the two potential start codons of mEGFP
while varying the mismatched base (Fig. 1a, Fig. 2). The best
replacement for the T-T mismatch on the first start codon was 2’-
Fluorouracil (FU), while for the A-A mismatch on the second start
codon 2-Aminopurine (AM) was best, each giving a ,2-fold
increase in mEGFP correction efficiency (Fig. 2a,b). To test
whether the increased efficiency in mEGFP correction by the
modified bases was due to avoidance of MMR, we transfected cells
with validated shRNAs plasmids targeting MSH2 and MLH1(Ta-
ble S2), then tested the mEGFP correction efficiency using oligos
with the different modified bases. Downregulating either MSH2 or
MLH1,as confirmed by western blotting (Figure S3a), lead to a ,
2-fold increase in mEGFP targeting efficiency in both the T-T and
the A-A mismatched oligos (Fig. 2c,d). However, this increase was
significantly lower for FU-T (Student t-test p-val=1.26E-5 for
MLH1, 3.42E-5 for MSH2) and somewhat lower for AM-A
mismatch (p-val=0.07 for MLH1). Interestingly, FA seems to be
more strongly recognized by MMR than the natural base,
suggesting an alternate mechanism is producing the increase in
targeting efficiency observed. These results were verified by
targeting MSH2 and MLH1 with siRNAs (Figure S3b,c). Thus,
silencing MSH2 and MLH1 decreased the gap in targeting
frequencies seen between the natural and modified bases,
suggesting that the increase in targeting efficiency by oligos
containing modified bases can be explained in part due to
avoidance of MMR.
Phosphorothioate Modifications Correlate with Oligo
Transfection Toxicity
By integrating an oligo into the transcribed strand of mEGFP
during DNA replication, oligo incorporation can be quantified
early, since transcription and translation of EGFP can already take
place before cell division. Aarts et. al. [25] showed that post-
replication/pre-division corrected cells each contain only one
Human Gene Targeting Oligos with Modified Bases
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36697Figure 1. Oligo-mediated targeting reporter system. (a) Reporter consists of a HeLa cell line with two stably integrated copies of EGFP with a
mutated TTG start codon and a second potential start codon (AAG) downstream, both shown in red. Each mutated start codon can be targeted by
sense or antisense oligos. Representative oligos used in this study are highlighted, in duplex form, with the mismatch shown by an asterisk. Further
detail can be found on Table 1. (b) Sample flow cytometry dot plot of cells with no oligo (left) or transfected with F5-8 (right, Table 1). The frequency
of oligo-induced correction of a start codon can be estimated as the %EGFP+/Propidium Iodide- cells (c) %EGFP+ cells generated after different oligo
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two rounds of cell division only 25% of cells stemming from the
original EGFP+ population will still be EGFP+. However, we
tracked the percentage of EGFP+ cells generated with oligo F5-3
over time and found an even greater decrease than expected; after
5 days EGFP+ had dropped to undetectable levels (not shown).
transfections, with and without 20 mM thymidine, assayed 36 h post transfections. Oligo sequences are shown 5’ to 3’, and the PTO bonds are
highlighted in gray. The control oligos F5-1 and F5-6 did not produce any significant proportion of EGFP+ cells, neither did F5-2, which is
complementary to the transcribed strand and encodes an ATG-restoring mutation. The oligos targeting the first and second potential start codons on
the non-transcribed strand, F5-3 and F5-5 respectively, did produce EGFP+ cells. Lipo=lipofectamine only control. n=4.
doi:10.1371/journal.pone.0036697.g001
Table 1. Oligonucleotides used in this study.
Oligo name Sequence
Corresponding Fig. 1
strand
F5-1 C*C*T*T*G*C*TCACCAAGGTGGC*G*G*A*A*T*T F5-1
F5-2 A*A*T*T*C*C*GCCACCATGGTGA*G*C*A*A*G*G F5-2
F5-3 C*C*T*T*G*C*TCACCATGGTGGC*G*G*A*A*T*T F5-3
F5-4 A*G*C*T*C*C*TCGCCCTTGCTCA*C*C*A*a*G*G F5-4
F5-5 A*G*C*T*C*C*TCGCCCATGCTCA*C*C*A*A*G*G F5-5
F5-6 A*G*C*T*C*C*TCGCCCGTGCTCA*C*C*A*A*G*G F5-3
F5-7 C*C*T*T*G*C*TCACCAdUGGTGGC*G*G*A*A*T*T F5-3
F5-8 C*C*T*T*G*C*TCACCAFuGGTGGC*G*G*A*A*T*T F5-3
F5-9 A*G*C*T*C*C*TCGCCCFaTGCTCA*C*C*A*A*G*G F5-4
F5-10 A*G*C*T*C*C*TCGCCCAmTGCTCA*C*C*A*A*G*G F5-4
F5-11 C*C*T*T*G*C*TCACCATGGTGGCGGAATT F5-3
F5-12 CCTTGCTCACCATGGTGGC*G*G*A*A*T*T F5-3
F5-13 C*C*T*TGCTCACCATGGTGGCGGA*A*T*T F5-3
F5-14 C*C*T*T*G*CTCACCATGGTGGCG*G*A*A*T*T F5-3
F5-15 C*C*T*T*G*C*T*CACCATGGTGG*C*G*G*A*A*T*T F5-3
F5-16 C*C*T*T*G*C*T*C*A*CCATGGT*G*G*C*G*G*A*A*T*T F5-3
F5-17 CCTTGCTCACCAFu*G*G*TGGCGGAATT F5-3
F5-18 CCTTGCTCACCAFu*G*G*T*G*G*CGGAATT F5-3
F5-19 C*C*T*T*G*C*TCACCAFuGGTGGC*G*G*A*A*T*T F5-3
F5-20 CCTTGCTCACCAA*G*G*TGGCGGAATT F5-1
F5-21 CCTTGCTCACCAFuGGTGGCGGAATT F5-3
F5-22 CCTTGCTCACCAFu*GGTGGCGGAATT F5-3
F5-23 CCTTGCTCACCAFu*G*GTGGCGGAATT F5-3
F5-24 CCTTGCTCACCAFu*G*G*T*GGCGGAATT F5-3
F5-25 CCTTGCTCACCAFu*G*G*T*G*GCGGAATT F5-3
F5-26 CCTTGCTCACCAFu*G*G*T*G*G*C*GGAATT F5-3
F5-27 CCTTGCTCACCAFu*G*G*T*G*G*C*G*GAATT F5-3
F5-28 CCTTGCTCACCAFu*G*G*T*G*G*C*G*G*AATT F5-3
F5-29 CCTTGCTCACCAT*G*G*TGGCGGAATT F5-3
F5-30 CCTTGCTCACCAFuGGTGGCGGA*A*T*T F5-3
F5-31 AATTCCGCCACCA*T*G*GTGAGCAAGG F5-2
F5-32 AATTCCGCCACCAm*T*G*GTGAGCAAGG F5-2
F5-33 CCTTGCTCACCAFu*A*G*TGGCGGAATT F5-3
F5-34 CCTTGCTCACCAFu*A*G*GTGGCGGAAT F5-3
F5-35 CCTTGCTCACCAT*A*G*TGGCGGAATT F5-3
F5-36 CCTTGCTCACCAT*A*G*GTGGCGGAAT F5-3
F5-37 Cy5-GGCTCCTTCAGCT*G*T*GAGACTACGT n/a
F5-38 CCTTGCTCACCAFu*G*G*TGGmCGGAATT F5-3
Sequences shown 5’ to 3’. PTO bonds shown as asterisks (*). dU=deoxyUridine, Fu=2’-Fluorouracil, Fa=2’-Fluoroadenine, Am=2-Aminopurine, mC=5-Methyl
deoxyCytidine.
doi:10.1371/journal.pone.0036697.t001
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slower than the non-corrected cells or dying. To distinguish these
possibilities we sorted corrected single cells 48 hrs post F5-3 oligo
transfection into 96-well plates. After multiple attempts, no EGFP+
clones were detected even when using oligos with the FU base
analog, suggesting that corrected cells were unable to proliferate.
This is in agreement with the results from Liu et. al. [30], who
were also unable to generate stably corrected clones with this
HeLa F5 cell line.
PTO modifications are used to protect oligos from nuclease
degradation, however this modification has been reported to be
toxic to cells [30]. To quantify this toxicity in relationship to
mEGFP targeting efficiency we varied the number of PTO
modifications in the targeting oligos and measured the effects on
both cell survival and correction efficiency after 48 hrs. We found
a clear trend where increased number of PTO bonds results in
lower survival of cells 48 hrs after oligo transfection (Figure 3a),
consistent with PTOs being toxic. In addition, an oligo with PTOs
only at the 3’ end (F5-12) leads to higher correction efficiency than
one with PTOs only at the 5’ end (F5-11, Fig. 3a). Interestingly,
mEGFP correction steadily decreased with additional PTOs when
there were more than six at each end. These results suggested that
finding a balance between toxicity and efficiency might be
necessary for generating stably corrected cells.
Cells Corrected with Less-protected Oligos are More
Likely to Proliferate
We hypothesized that reducing the number of PTO bonds
might increase the number of proliferating EGFP+ cells. However,
since reducing the number of PTO bonds also decreases targeting
efficiency, we decided to concentrate on protecting the 3’ end.
Furthermore, we decided to test internally protected oligos, since
these have been found to lead to higher survival rates [20]. We
designed two new oligos with three or six PTO bonds 3’ to the
centrally located mismatch, all using a FU base analog (Table 1,
Fig. 3b). Previous work has described the defect in oligo-corrected
cells as a G2/M cell cycle arrest [20–21,24], with few cells moving
past it. In order to generate a more detailed view of the effects of
oligos on proliferation, we tracked cells using the CellTrace Violet
dye [31–32] (Figure 4a). This allowed us to follow the relative
proliferation rate of the corrected (EGFP+) and uncorrected
(EGFP-) cell populations by flow cytometry as the inverse dilution
rate of the CellTrace dye’s Mean Fluorescent Intensity (MFI)
(Figure 4b). First, we observe that in general EGFP+ cells
proliferate slower than corresponding EGFP- cells. Second, the
proliferation of EGFP+ cells inversely correlates with the number
of PTO bonds of the oligo used to generate them, with the EGFP+
cells from the F5-8 (12 PTO) oligo hardly proliferating and the F5-
18(6 PTO) having an intermediate phenotype. The proliferation
rate of corrected cells depended on the number of PTO bonds on
the oligo, suggesting it is the correcting oligo itself and not the
expression of EGFP the cause of their proliferation defect. To
functionally validate this observation, we treated F5-17 transfected
cells with anti-microtubule drugs, which are preferentially toxic to
proliferating cells [33], 24 hrs post-transfection (Fig. 4c). This
produced an increase of EGFP+ cells at 48 and 96 hrs, suggesting
that non-corrected cells had been preferentially inhibited, and
therefore that corrected cells experience delayed proliferation. To
verify that the effects of the anti-microtubule drugs were not due to
endosome destabilization leading to increased oligo release, cell
were treated with chloroquine, which actually slightly decreased
targeting frequencies (not shown).
In the case of the F5-17 oligo, the EGFP+ cells seemed to
achieve a proliferation rate similar to the uncorrected EGFP- cells
eight days post-transfection, since the percentage of positive cells
remained constant between 144 and 192 hrs (Fig. 4a) and when
checked again after a few weeks of passaging (not shown). By
doubling the amount of lipofectamine:oligo complex we were able
to double the frequency of corrected cells to ,0.05% eight days
post-transfection (Figure S4). We chose this time point to repeat
our single-cell sorting assay and found that EGFP+ cells generated
with the F5-17 oligo easily generated clonal populations. These
clones were verified by sequencing and found to have the desired
genome modification (Figure S5a). To verify that this modification
was not due just to spontaneous mutations, we repeated the
experiment with oligos that introduced two adjacent nucleotide
changes, one of which would restore the ATG start codon of
mEGFP (using either a T or FU base) and other of which would
introduce either a second substitution or a single-base insertion
(Fig. 5). As expected, efficiency of incorporation of double-mutant
oligos was significantly lower than for single-substitution oligos,
Figure 2. Chemically-modified base analogs. (a–b)Modified base-
containing oligos complementary to the non-transcribed strand’s (a)first
potential start codon TTG and (b) second potential start codon AAG,
where each mismatched base X in the targeting oligo is shown in
parenthesis. (c–d) RNAi targeting key mismatch repair proteins MLH1
and MSH2 for the (a)TTG and (b)AAG start codon targeted by oligos
containing modified bases. Data was normalized relative to scr shRNA,
thus in (c) each MMR component silencing produced a 2-fold
improvement for the natural T base, while the improvement for FU
was reduced. This is seen to a lesser degree in (d) comparing A and AM,
while FA was further improved, suggesting it is more strongly
recognized by MMR. n=4.
doi:10.1371/journal.pone.0036697.g002
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substitution-and-insertion. Interestingly, using the FU base had an
adverse effect in the double-substitution, suggesting a more
complex mismatch recognition effect when more than one
substitution is involved. Although the correction efficiencies were
low, it was possible to sort EGFP+ cells generated with all four
oligos, and all clones proliferated normally and were verified by
sequencing to be correctly modified(Figure S5b,c).
To further elucidate oligo design principles, we checked for
long-term survival of EGFP+ cells two weeks after transfection
while varying the number of PTO bonds 3’ to the mismatch
(Figure 6a). This showed 3-5PTO bonds as optimal, resulting in at
least ,10-fold increase in targeting efficiency compared to
unmodified oligos. We also varied the position of the PTO bonds,
the strand polarity of the oligo used and the presence of modified
bases (Figure 6b). When using an oligo complementary to the
transcribed strand (F5-31, -32) we were able to detect some
EGFP+ cells, but only slightly above the control oligo F5-20,
suggesting the strand bias against the transcribed strand observed
in this cell line is not just due to the additional DNA replication
necessary to express the corrected gene when targeting this strand.
Comparing the presence of 3PTO bonds at the 3’ terminus (F5-30)
vs. 3’ internal to the mismatch (F5-17) produced a ,4-fold
reduction in EGFP+ cells, confirming that internal PTO
modifications result in higher stable targeting frequencies.
Comparing the natural (F5-29) and modified (F5-17) base oligos
resulted in a similar 2-fold increase for the modified base as when
assayed 48 hrs after transfection. Thus, optimizing the oligo design
with modified base analogs and reducing the number of PTO
bonds enabled us to generate stable, isogenic populations
genetically modified with oligos.
The Proliferation Defect in Corrected Cells may be
Associated to a Cellular Immune Response to Transfected
Oligos
Our results suggest that the PTO modification in the oligos is
the main reason corrected cells proliferate slower, rather than the
mismatch generated by the oligo incorporation. Currently, the
principal mechanism associated with PTO-modified oligo toxicity
is the generation of DNA double-strand breaks. To check this we
measured the levels of c-H2AX phosphorylation in oligo
transfected cells by flow cytometry (Figure S6), and find that
reducing the number of PTO bonds reduced the levels of c-H2AX
phosphorylation. Interestingly, this also showed that EGFP+ cells
had lower levels of c-H2AX phosphorylation when compared with
the non-corrected EGFP- cells treated with the same oligo. This
suggests that although c-H2AX phosphorylation may be a general
marker of oligo toxicity, DNA double-strand breaks might not be
the cause of decreased proliferation of oligo-modified EGFP+ cells,
or at least not the only cause.
To further explore the proliferation defect in corrected cells, we
sorted EGFP+ and EGFP- cells 36 hrs after transfection with the
F5-17 oligo and performed RNA-seq to compare the two
Figure 3. Varying PTOs in targeting oligos. All oligos in this figure are complementary to the non-transcribed strand’s first potential start codon
TTG, similar to F5-3 in Fig. 1. (a) Oligo toxicity and targeting efficiency as a function of PTO modifications. PTO bond position shown in gray. ‘Total
alive cells’ was estimated as the total gated PI- cells in 200 uL from a 24-well plate 48 hrs post oligo transfection. (b) Correction efficiencies of new
oligo designs with reduced PTO bonds and using FU modified base. n=4.
doi:10.1371/journal.pone.0036697.g003
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differentially regulated genes (400 genes, p,10
270) between
corrected and uncorrected cells (Dataset S1). We analyzed this
top 400 gene list with ToppFun(http://toppgene.cchmc.org) to
look for enrichment on any Gene Ontology categories. Interest-
ingly ‘viral reproduction’ and ‘viral infectious cycle’ were among
the most highly represented (Table S4).
To further explore this observation, we choose three highly
differentially expressed genes known to be involved in antiviral/
cellular immune responses: HLAB, IL32 and OAS3. We validated
these genes by RT-qPCR, which allowed us to normalize the
expression levels of corrected and uncorrected cells to untrans-
fected cells(Fig. 7a). This revealed much higher induction levels for
both populations relative to untransfected cells. For F5-17, the
difference between transfected and untransfected cells was much
higher (8–30 fold) than between EGFP+ and EGFP- cells (2–4
fold), suggesting that both non-corrected and corrected cells share
an ‘oligo-transfected’ transcription profile. To verify that the gene
changes were not due to EGFP itself, we checked the expression
levels of EGFP+ and EGFP- cells after transfection with the F5-18
oligo. Like F5-17, F5-18 also generates EGFP+ cells, but F5-18 is a
more toxic oligo as it contains three additional PTO bonds. If the
upregulation of the three immune response genes we had observed
were due to effects of the EGFP protein and not oligo toxicity,
EGFP+ or EGFP- cells should have similar expression of these
genes whether they had been transfected with F5-17 or F5-18. In
contrast, however, the F5-18 transfected cells showed proportion-
ally higher levels of induction of the three genes relative to F5-17,
with EGFP+ cells still ,2-4 fold higher than EGFP- cells. One
possible explanation for the difference between corrected and
uncorrected cells would be that corrected cells got more oligos
during transfection. We tested this by co-transfecting a targeting
oligo along with a Cy5-labled one (F5-37). This showed that
EGFP+ cells consistently had 2–5 times higher levels of oligos at
varying oligo concentrations (Fig. 7b), suggesting that corrected
cells may be proliferating less due to relatively higher oligo
concentrations inducing a stronger immune response. Oligos with
higher number of PTO modification have increased half-lives,
which might lead to higher immune stimulation.
One possible cause for the immune response to the transfected
oligos would be the presence of an unmethylated CpG in the oligo
sequence. We tested an oligo with a methyl-C modification (F5-38,
Table 1), but this had no effect on the percentage of EGFP+ cells
after oligo transfection (Figure 7c). This is not unexpected
however, since non-CpG-containing oligos have also been found
to activate inflammatory responses [34]. Additionally, we tested
small-molecule inhibitors targeting key immune signaling path-
ways, out of which NEMO inhibition produced a ,2-fold increase
in the percentage of EGFP+ cells (Figure 7d). This increase,
however, did not translate to higher survival eight days post-
transfection(not shown). Further work is needed to determine the
specific immune signaling pathway that might be induced in oligo-
mediated targeting. Inhibiting such pathway may reduce the
toxicity of PTO-modified oligos, leading to further improvements
in targeting efficiencies.
Discussion
In this work we describe our progress towards oligo-mediated
genome engineering in human cells. An efficient version of this
Figure 4. Proliferation defect in corrected cells. Proliferation is inversely proportional to the MFI of the CellTrace Violet dye. Cells were treated
with CellTrace Violet dye, then split and transfected with oligos 48 hrs later. Cells were fixed at each time point and run together on a LSRfortessa cell
analyzer at the end of the time course (a) Flow cytometry dot plots showing relative proliferation of EGFP+ and EGFP- cells generated with different
targeting oligos, at four different time points post-transfection. %EGFP shown as average6s.d. n=6. (b) Proliferation index is calculated as the inverse
MFI of CellTrace610
6 for each population. (c) Cells treated with anti-microtubule drugs Taxol and Vincristine 24 h after transfection with oligo F5-17
and 24 h exposure time, checked at 48 h and 96 h post-transfection. n=4.
doi:10.1371/journal.pone.0036697.g004
Figure 5. Generating double mutants. Oligos complementary to the first start codon in the non-transcribed strand and containing a second
mismatch, either an insertion (ˆA) or substitution (-A), with silenced MSH2 and assayed 36 hrs after transfection. Targeting oligos shown in duplex 3’-
to 5’-, with PTO highlighted in gray and mismatches shown with an asterisk. F5-20 was used as non-correcting control. n=4.
doi:10.1371/journal.pone.0036697.g005
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design of custom proteins such as ZFNs or TALENs, simplifying
experimental design and reducing time and costs. Currently,
however, oligo-mediated genome engineering in human cells is
severely limited by both low oligo incorporation efficiency and the
low survival of modified cells. The nature of this limitation is likely
multifactorial, with DNA damage being the most studied so far
[21], [24]. Recent evidence in bacterial and mammalian systems
suggests a model of oligo incorporation during DNA replication.
Thus, when the oligo carrying the desired genetic change gets
incorporated, it can be detected as a DNA replication error by the
MMR machinery. The cause of low survival of corrected cells is
unknown, but is at least partly caused by the cytotoxicity of the
oligos.
To reduce the impact of MMR on oligo-mediated correction
efficiency, we tested if using chemically modified base analogs
capable of avoiding MMR recognition in E. coli would have a
similar effect in human cells. As in E. coli, we found that FU and
AM outperform thymine and adenine, respectively, in creating T-
T or A-A mismatches leading to A/T transversions. By transiently
silencing MSH2 and MLH1 we found that, at least for FU, the
increased targeting efficiency of these modified bases is in part due
to avoidance of the MMR machinery. This effect, however, seems
to be complex since adding a second mismatch produced variable
results (Figure 5), likely due to sequence context effects [35].
Because our reporter assay is limited to restoring the start codon of
mEGFP, we were only able to study modified bases substituting A
and T, but we expect that other modified bases found to work in E.
coli will have a similar effect. Further work is required to fully
elucidate the mechanism by which modified bases increase
targeting frequencies in different human cell types. This is
especially true for the modified base FA, since it is being
recognized more strongly by MMR than the native A base, yet
it is still capable of increasing targeting efficiencies. It is possible
that other MMR components, or additional DNA repair pathways
such as NER might be responsible for recognizing this base, as it
has been suggested that these two pathways may functionally
overlap [36–37]. An advantage of using modified bases rather than
suppressing the endogenous MMR machinery to increase oligo
incorporation efficiency is the avoidance of unwanted mutations
elsewhere in the genome that MMR suppression is likely to lead to
[38], essential for functional genomics and potential gene therapy
applications.
Using FU for MMR-avoidance in an oligo containing 6PTO
bonds on each end lead to a substantial number (,3–5%) of
EGFP+ cells shortly after transfection, however this EGFP+
population did not proliferate further. This suggests that a process
other than MMR-mediated DNA damage signaling may be
Figure 6. Effects of PTO in long-term survival of corrected cells. (a) Varying numbers of PTO bonds 3’ to the mismatch, shown in gray,
suggest 3-5PTO bonds as optimal for balancing toxicity and stable targeting frequencies, assayed 14-days after oligo transfection by flow cytometry.
(b) Testing the position of PTO bonds, strand targeted and use of modified bases in long term survival. F5-20 used as non correcting control, F5-17, -
29 and -30 are complementary to the non-transcribed strand, while F5-31, -32 are complementary to the transcribed. n=4.
doi:10.1371/journal.pone.0036697.g006
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been previously implicated in oligo cytotoxicity, we tested varying
the number and position of PTO bonds. We found a clear trend
where a higher number of PTO bonds lowers the total number of
cells surviving after transfection. Additionally, protecting only the
3’ end yielded a higher percentage of corrected cells than a
similarly protected and similarly toxic 5’ end. Based on this, we
designed two new oligos with a reduced number of PTO bonds 3’
to the mismatch and used these to examine cell proliferation after
transfection in more detail. Using a cell tracking dye we found that
the proliferation of corrected cells was consistently lower than that
of uncorrected ones, and that the proliferation of corrected cells
was increased when the targeting oligo contained a lower number
of PTO bonds. The F5-17 oligo allowed us to isolate stably
modified EGFP+ cells with the correct genotype. This oligo’s three
PTO bonds are situated immediately 3’ to the mismatch base and
are therefore internal to the oligo. The oligo would be reduced to
only 16 bases long by 3’-5’ exonucleases, which might make
annealing inefficient. We speculate instead that internal-3’
protection might prevent removal of oligos by proofreading
polymerases after annealing while still allowing sufficient clearance
of excess oligo by autonomous exo- and endonucleases. Support-
ing this, F5-30, a similar oligo but with the 3 PTO bonds at the 3’
terminal resulted in a ,4-fold decrease in survival compared to
F5-17. To try and elucidate the cause of oligo toxicity in relation to
PTO bond number we measured the levels of c-H2AX
phosphorylation. We find that the number of PTO bonds directly
correlates to the levels of c-H2AX phosphorylation, but EGFP+
cells have consistently lower levels than EGFP- cells, which
counters observations on other cell lines [24–25]. The fact that
HeLa cells have abnormal p53 signaling might account for the
observation that EGFP+ cells have lower levels of c-H2AX
Figure 7. Induction of immune-related genes in oligo-transfected cells. (a)RT-qPCR relative quantification was performed for key immune-
related genes, normalizing oligo-transfected to untransfected cells. (b) Mean Fluorescence Intensity (MFI) of total and EGFP+cells transfected with
both F5-17 and F5-38 (Cy5-labeled) oligo at varying concentrations. Transfections were done in 24-well plates. n=4 (c) Methylation of the CpG
sequence present in the targeting oligo has no effect on the %EGFP+ cells. (d) Small-molecule inhibitors against key immune effectors, with DMSO as
control, added 24 h after F5-17 oligo transfection assayed for EGFP+ cells at 48 h and 96 h. n=4.
doi:10.1371/journal.pone.0036697.g007
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observed double-strand breaks were an indirect consequence of
oligos inducing apoptosis [39] rather than the breaks being directly
caused by the oligos. Future investigation into the mechanisms of
PTO toxicity and targeting oligo protection would be desirable.
The dot plots from our cell proliferation experiments show that
modified cells are a subset of the population with a proliferation
defect. To get a better understanding of this growth phenotype we
did RNA-seq to compare the transcription profiles between
corrected and uncorrected cells. This revealed a large number of
mildly differentially expressed genes between the two populations,
especially genes involved in immune/viral processes, based on GO
category enrichment. Interestingly, DNA damage-associated GO
categories had a much less significant p-value (,10
22 vs. ,10
230),
further arguing against DNA damage causing the low survival of
corrected cells. We validated the differential expression of HLAB,
OAS3 and IL32 to use as immune response markers by RT-qPCR,
which in addition allowed us to compare expression levels to those
of untransfected cells and of cells treated with different targeting
oligo designs. This uncovered two important clues: first, both
corrected and uncorrected cells showed a much higher fold
induction of immune genes than untransfected cells and second,
more oligo PTO modifications lead to proportionally higher
expression levels. Since cells that get more oligos during
transfection are presumably more likely to become EGFP+,w e
believe that higher oligo concentrations within corrected cells may
be inducing a stronger cellular immune response. A similar effect
may also explain the toxicity of PTO modifications, since PTO
modifications stabilize oligos and will therefore lead to higher
sustained oligo concentrations after transfection, which in turn
may lead to higher immune signaling. Alternatively, it is possible
that cellular DNA sensors might recognize the abnormal PTO
backbone itself [40]. Functional studies are currently underway to
further explore this observation. The model of oligo-mediated
immune response seems plausible, especially in light of the
growing list of cellular immune DNA sensors [40–42] and the
role of 3’ exonucleases in inflammatory diseases [43]. It is possible
that the immune response triggered in oligo corrected cells might
affect cellular phenotype in such a way that it confounds the effects
of the targeted mutation itself. This could be assayed by expanding
our comparison of transcriptional profiles of modified clonal
populations to include comparisons against profiles of the
unmodified ‘parental’ line. If necessary and depending on the
intended study, mutations of interest could be evaluated in parallel
with silent mutations to control for the modification process.
Further work is necessary to better understand the roles of DNA
double-strand breaks and cellular immunity in oligo-mediated
toxicity, including testing these observations in different cell lines.
The wealth of sequencing projects and GWAS’s data will
necessitate novel methods for experimentally testing human
genetic variants. For modeling a few high-interest single-loci
isogenic changes by targeted manipulation of human cell genomes,
the current state-of the-art method of ZFNs + ssOligo [8] performs
well. However, screening of hundreds of polymorphisms and their
potential combinatorial interactions for phenotypic effects is not
currently feasible with these methods. An oligo-mediated genome
engineering method as used in E. coli [16] is far better suited for
this, where up to ten simultaneous oligo incorporations are
possible (Carr P.A. and Wang H.H., in revision), and experimental
design is trivial and without the need of custom DNA-binding
proteins. We estimate our current targeting frequency to be
,0.05% for HeLa cells. This level of targeting efficiency should
easily allow the generation of isogenic cells by using a pooled
genotyping serial enrichment strategy [29] [38]. The cellular
immune response to transfected oligos described here represents a
novel and exciting avenue which might lead to further reduction of
toxicity and thus improved targeting efficiencies in multiple cell
types. We are working to develop oligo-mediated genome
engineering in human induced pluripotent stem cells, which could
enable combinatorial testing of genetic variants in multiple tissues
simultaneously, greatly expediting the study of human genetic
variation and the genetic basis of human disease.
Materials and Methods
Cell Culture and Transfections
The HeLa F5 cell line was kindly provided by Dr. Depei Liu.
These were cultured in DMEM with GlutaMAX and HEPES,
supplemented with 10% HI-FBS, 100 mg/ml streptomycin and
100 U/ml penicillin (Invitrogen) at 37uC and 5% CO2 in a
humidified incubator. Cells densities were determined using the
Countess Automated Cell Counter (Invitrogen). For subculturing,
cells were washed with PBS pH 7.4, trypsinized with TrypLE
Express(Invitrogen) and neutralized with 10% HI-FBS DMEM.
Oligo Transfections
HPLC-purified oligos were ordered from Integrated DNA
Technologies, resuspended in distilled water and their concentra-
tions verified by NanoDrop (Thermo Scientific). Cells were pre-
seeded at 3610
6 cells per 10 cm plate two days before transfection.
Pre-seeded cells were split to 100,000 cells/well for a 24-well plate
or at 3610
6 cells for a 10 cm plate. The next day, cells were
washed with PBS and 10% HI-FBS with no antibiotics was added.
Transfections were done with Lipofectamine 2000 (Invitrogen)
using a 3:1 ratio of mL lipofectamine to mg oligo. For 24-well
plates, 0.5 mg of oligo and 1.5 mL lipofectamine were diluted in
25 mL OptiMEM(Invitrogen) each, incubated at room tempera-
ture for 5 mins, combined by pipetting, then incubated again for
20 mins. The oligo complexes were added to cells dropwise and
cultured continuously for 36–48 hrs. Unless otherwise noted,
20 mM thymidine was added to the cells two hours prior
transfection.
Flow Cytometry Analysis
After 36–48 hrs, oligo-transfected cells were washed with PBS,
trypsinized, neutralized with 10% HI-FBS DMEM and trans-
ferred to 96-well U-bottom plate. Death exclusion was done with
10% propidium iodide (Roche), and total surviving cells were
estimated as the total number of living cells counted at a
determined volume. The plate was run on a five-laser BD
LSRFortessa HTS with FACS Diva 6.1 software. EGFP was
detected with the 488 nm laser, 530/30 nm filter; CellTrace
Violet with the 405 nm laser, 450/50 nm filter; propidium iodide
with the 561 nm, 610/20 nm filter; Cy5 with 640 nm laser, 670/
30 nm filter. Cell sorting was performed on a BD FACSAria II
SORP equipped with 375 nm, 405 nm, 445 nm, 488 nm,
561 nm, and 633 nm lasers.
Genotyping and Sequencing
We used allele-specific realtime PCR to quantify corrected
versus uncorrected mEGFP DNA in cells after oligo targeting. A
152 bp amplicon was amplified using a forward primer whose 3’
terminal base matched either the uncorrected or corrected mEGFP
target site. Using standard curves for each primer pair, a ratio of
corrected to non-corrected template strands could be estimated for
each cell population. EGFP+ and EGFP- cells were sorted by
FACS and pelleted. To lyse the cells, ,1,500 cells resuspended in
8.9 ml water were added to 1 ml1 0 6 gold buffer and 0.1 mL
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then 95uC for 5 min. The reaction was split into 265 mL and each
aliquot was mixed with 20 mL PCR mix containing the corrected-
specific or non-corrected-specific primer pair. PCR mix: 18.8 mL
1.1X Platinum Taq Supermix (Invitrogen), 0.5 mL each primer
(stock solution 10 uM), 0.2 mL SYBR green I (stock solution a
1:500 dilution of original tube). Realtime PCR was carried out on
an Opticon 2 DNA Engine (MJ Research), under the following
cycling conditions: 95uC for 3 min followed by 40 cycles of 95uC
30 sec, 62uC 30 sec, 72uC 30 sec. To sequence the mEGFP target
site in stable non-corrected and corrected cell clones, a similar
PCR protocol was used except with primers N1 and N3 from [27]
that span the targeted region. Single-cells were sorted eight days
post-oligo transfection, and clonal populations were obtained after
growing for ,2 weeks. PCR products were sequenced by
Genewiz, inc. All PCR primer sequences used can be found in
the Table S1.
RNA Interference
HeLa F5 cells were seeded 3610
6 cells per 10 cm plate. The
next day, media was changed to 4 mL 10% HI-FBS with no
antibiotic. Transfection of validated shRNA plasmids (Sigma-
Aldrich) or scramble control (Addgene) was done with FuGENE
HD, diluting 15 mg of HiSpeed Maxi-Prep(QIAGEN) purified
plasmid and 60 mL of FuGENE HD(Roche) in 500 mL OptiMEM
each. The dilutions were mixed by pipetting and incubated for
15 mins before adding complexes dropwise to plates. After
overnight transfection, cells were washed, trypsinized and re-
seeded in 10 cm plates with 10% HI-FBS DMEM and 3 mg/mL
puromycin (Sigma-Aldrich) After two days of puromycin selection,
cells were split into 24-well plates 100,000 cells/well for oligo
transfections. shRNA target sequences can be found in Table S2.
Cell Proliferation Assay
HeLa F5 cells seeded at 3610
6 cell per 10 cm plate were
washed and incubated in 5 mL PBS with 10 mM CellTrace
Violet(Invitrogen) for 10 mins at 37uC, washed and grown in 10%
HI-FBS DMEM overnight. Cells were split and pre-seeded at
3610
6 cell per 10 cm plate, then the next day seeded in 24-well
plates for oligo transfection. At each timepoint, cells were
trypsinzed, centrifuged at 500 g for 5 mins and fixed in 4% PFA
(Biolegend) for 20 min in the dark at room temperature. After
another centrifugation, cells were resuspended in Cell Staining
Buffer (Biolegend) and kept at 4uC. After the last timepoint
samples were run together on a BD LSRFortessa HTS.
Anti-microtubule Drug Treatment
Twenty-four hours after cells were transfected with oligos,
media was changed and cells were exposed to varying concentra-
tions of either Taxol or Vincristine (EMD) for 24 hours, then
washed and assayed with the BD LSRFortessa HTS immediately
or two days later (96 hours after oligo transfection).
RNA-seq and qPCR
HeLaF5cellsplatedat3610
6cellsona 10 cmplatewerewashed
and 4 mL of OptiMEM with 20 mM thymidine was added two
hours prior transfection with 15 mg oligo/45 mL lipofectamine.
Thirty-six hours after transfection cells were trypsinized, filtered
through a 35 mm cell strainer (BD Bioscience #352235), counted
and centrifuged at 250 g for 5 mins. Cells were resuspended at a
density of 1610
7 cells/mL in 20% HI-FBS DMEM and sorted into
EGFP+ and EGFP- directly into Trizol LS(Invitrogen). Extracted
RNA was precipitated and concentrated on a RNAeasy Micro kit
column (QIAGEN ), and the quality of RNA was determined in an
Agilent 2100 Bioanalyzer. Each sorting was done from 15 10-cm
plates of transfected cells and the RNA of three independent sorting
sessions was pooled to ,2 mg of total RNA. RNA-seq was
performed as described [44] with some modifications, i.e. there
was no normalization of the library. Reads were aligned using
TOPHAT and reads mapping to each gene were analyzed for
differential expression with a Bayesian statistic [45]. For RT-qPCR,
first-strand synthesis was done with the SuperScript III kit
(Invitrogen), and qPCR with the KAPA SYBR Fast Universal 26
mix following manufacturer’s protocol. The sequence of the IDT-
synthesized qPCR oligos can be found in Table S2. The reaction
was assayed in a DNA Engine Opticon2 instrument (MJ Research).
Small Molecule Immune Inhibitors Drug Treatment
After cells were transfected with oligos for 24 hours, media was
changed and cells were exposed 5 mM IKK inhibitor VI, 50 mM
IRAK1/4 inhibitor, 20 mM Cell-Permeable NEMO-Binding
Domain Binding Peptide, NF-kB SN50, 36 mM Cell-Permeable
Inhibitor Peptide and 10 mM JNK Inhibitor II (EMD) for 24 hours
then assayed with the BD LSRFortessa HTS immediately or two
days later (96 hours after oligo transfection).
Supporting Information
Figure S1 Nuclear localization of transfected oligos.
Cells were grown in glass-bottom 24-well plates and stained with
Hoechst 33342 10 ug/mL. The next day, cells were transfected
with 500 ng fluorescein-labeled oligo using various cationic lipid
reagents following manufacturer instructions and imaged 24 hours
after transfection. Scale bar=10 mm ea.
(TIFF)
Figure S2 Oligo delivery and correction efficiencies
using various transfection reagents. Cells were plated
100,000 cells/well on a 24-well plate, n=4. (a) Cells were
transfected with a fluorescein-labeled oligo, and oligo delivered is
shown as the MFI of the total cell population. (b) Correction
frequencies with oligo F5-8 as a function of oligo amount.
(TIFF)
Figure S3 RNAi validation. (a) Western Blotting confirming
knockdown of MMR components. Primary antibodies anti-MSH2
(ab52266, 1:5,000), anti-MLH1 (ab92312, 1:2,000) and anti-Actin
(ab3280,1:10,000),and secondary antibodies anti-rabbit IgG (ab6721,
1:25,000) and anti-mouse IgG (ab6728 1:25,000) were obtained from
Abcam. (b), (c) siRNA targeting mismatch repair components have a
lower effect with modified bases. A 24-well plate was treated with
80 nM siRNA, 1 uL RNAiMax following manufacturer’s protocol.
siRNA-treated cells were transfected with targeting oligos 72 hrs later.
n=4 siRNAs sequences can be found in Table S3.
(TIFF)
Figure S4 HeLa F5 cells transfected with F5-17 oligo,
either 1x or 2x DNA:lipofectamine complexes, assayed
for %EGFP+ cells eight days after transfection.
(TIFF)
Figure S5 Sequencing corrected EGFP+ clonal cells.
Single-cells were sorted into a 96-well plate 8 days post-
transfection with (a) F5-17,(b)F5-34, (c)F5-35, grown for two
weeks and then sequenced. Sequence spectrum overlap shows one
of the two mEGFP copies was modified.
(TIFF)
Figure S6 c-H2AX phosphorylation staining. Cells were
plated 500,000/well on a 6-well plate, then transfected with the
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PLoS ONE | www.plosone.org 12 May 2012 | Volume 7 | Issue 5 | e36697corresponding oligos. After 36 hrs, cells were washed, fixed in
4%PFA, permeabilized with 10% saponin, then stained with Alexa
Fluor 647 anti-H2A.X-Phosphorylated Antibody (1:25, Biolegend)
shaking for 20 mins at room temperature.
(TIF)
Table S1 PCR primers sequences.
(DOCX)
Table S2 shRNAs sequences.
(DOCX)
Table S3 siRNA sequences.
(DOCX)
Table S4 Enriched GO categories. Top 400 genes based on
p-value were analyzed with Toppgene, showing strong representa-
tion of viral process category.
(DOCX)
Dataset S1 Top 400 hits from RNA-seq experiment.
GFP+ and GFP- refers to cells after treating with oligo F5-17.
(XLSX)
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